Skip to main content

7 Result(s)

within C. Exbrayat Remove this filter

and

  1. No Access

    Article

    Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania

    Tyrosine kinase inhibitor (TKI) discontinuation in chronic phase chronic myeloid leukemia (CML) patients has been examined in a real-life setting in the east occitania region of France. We have collected sex, ...

    J. B. Robin, A. Theron, P. Quittet, C. Exbrayat, J. B. Gaillard… in Annals of Hematology (2022)

  2. No Access

    Chapter and Conference Paper

    Analyse des cancers de l’intervalle du sein dans les départements français disposant d’un registre des cancers

    Depuis 2008, des travaux sur les cancers de l’intervalle sont réalisés régulièrement pour suivre les évolutions de la performance du programme de dépistage des cancers en France. La sensibilité de ce programme...

    C. Exbrayat, M. Barraud Krabe, C. Guldenfels… in Acquis et limites en sénologie / Assets an… (2013)

  3. No Access

    Chapter and Conference Paper

    Estimation du surdiagnostic lié au dépistage du cancer du sein par mammographie : étude en population générale

    Le dépistage du cancer du sein par mammographie entraîne une diminution de la mortalité par cancer du sein mais peut présenter certains effets indésirables comme l’inconfort de la mammographie, la présence de ...

    A. Seigneurin, O. François, J. Labarère… in Cancer du sein : surdiagnostic, surtraitem… (2012)

  4. No Access

    Article

    Association of diagnostic work-up with subsequent attendance in a breast cancer screening program for false-positive cases

    The objective of this study is to determine whether the likelihood of returning for routine breast cancer screening differed for false-positive cases depending on the diagnostic work-up. Using the original dat...

    Arnaud Seigneurin, C. Exbrayat, J. Labarère… in Breast Cancer Research and Treatment (2011)

  5. No Access

    Article

    Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients

    The use of a combination of G-CSF and GM-CSF versus G-CSF alone, after cyclophosphamide (4 g/m2) was compared in two randomized phase III studies, including 120 patients. In study A, 60 patients received 5 × 2 μg...

    P Quittet, P Ceballos, E Lopez, Z Y Lu, P Latry, C Becht… in Bone Marrow Transplantation (2006)

  6. No Access

    Article

    Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects

    Interleukin-6 (IL-6) is a major survival factor for multiple myeloma (MM) cells preventing apoptosis induced by dexamethasone (DEX) or chemotherapy. In all, 24 consecutive patients with MM in first-line therap...

    J-F Rossi, N Fegueux, Z Y Lu, E Legouffe, C Exbrayat… in Bone Marrow Transplantation (2005)

  7. No Access

    Article

    Enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy

    Non-myeloablative regimens have been proven to allow engraftment following allogeneic stem cells transplantation (allo-SCT) with minimal procedure-related toxicity. Conventional allo-SCT may produce remissions...

    M Mohty, N Fegueux, C Exbrayat, ZY Lu, E Legouffe, P Quittet… in Bone Marrow Transplantation (2001)